Emergent Biosolutions Stock News

In last trading session, Emergent BioSolutions Inc. (NYSE:EBS) saw 0.41 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $45.30 trading at $0.7 or 1.57% at ring of the bell on the day assigns it a market valuation of $2.38B. That closing price of EBS’s stock is … Emergent BioSolutions Inc. (NYSE:EBS) Is 34.04% Above Its 52-Week Low, But How Long Can It Continue? Read More »

Emergent BioSolutions <> is rising following an upgrade by Benchmark to Buy from Hold with a $77 price target, which represents 60% appreciation from the current share

Fuad El-Hibri to Retire After More Than 20 Years Fuad El-Hibri to Retire After More Than 20 Years

GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial guidance for 2022 and selected preliminary unaudited financial results for 20

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the followin

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following in

Austria's main stock market index is set to be the top performing Western European benchmark of the year.

New York State Teachers Retirement System reduced its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 6.5% during the third quarter, Holdings Channel reports. The institutional investor owned 54,486 shares of the biopharmaceutical companys stock after selling 3,802 shares during the quarter. New York State Teachers Retirement Systems holdings in Emergent BioSolutions were worth [] The post New York State Teachers Retirement System Sells 3,802 Shares of Emergent BioSolutions Inc. (NYSE:EBS) appeared first on ETF Daily News .

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tole

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the companys investigational universal influenza vaccine candidate. This current version of Emergents universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Emergent BioSolutions Inc. EBS, +3.55% said Thursday that it began dosing participants in a Phase 1 clinical trial for its universal influenza vaccine candidate. The randomized, double-blind, placebo-

Greenwood Capital Associates LLC trimmed its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 2.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,410 shares of the biopharmaceutical companys stock after selling 392 shares during the quarter. Greenwood Capital Associates []